Berenberg Bank analyst Iris Long maintained a Buy rating on Omnicell (NASDAQ:OMCL) on Tuesday, setting a price target of $173, which is approximately 0.84% below the present share price of $174.47.
Long expects Omnicell to post earnings per share (EPS) of $0.47 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Omnicell, with an average price target of $186.5.
The analysts price targets range from a high of $200 to a low of $173.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $272.74 million and a net profit of $28.92 million. The company's market cap is $7.58 billion.
According to TipRanks.com, Berenberg Bank analyst Iris Long is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 14.3% and a 80.00% success rate.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.